Clinical data | |
---|---|
Trade names | Humalog, Liprolog, Admelog, others |
Other names | URLi, LY900014, LY-275585, insulin lispro-aabc |
AHFS/Drugs.com | Monograph |
MedlinePlus | a697021 |
License data |
|
Pregnancy category |
|
Routes of administration | Subcutaneous |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C257H389N65O77S6 |
Molar mass | 5813.68 g·mol−1 |
3D model (JSmol) |
|
SMILES
| |
InChI
| |
(what is this?) (verify) |
Insulin lispro, sold under the brand name Humalog among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes.[3] It is delivered subcutaneously either by injection or from an insulin pump.[3][4] Onset of effects typically occurs within 30 minutes and lasts about 5 hours.[3] Often a longer-acting insulin like insulin NPH is also needed.[3]
Common side effects include low blood sugar.[3] Other serious side effects may include low blood potassium.[3] Use in pregnancy and breastfeeding is generally safe.[5] It works the same as human insulin by increasing the amount of glucose that tissues take in and decreasing the amount of glucose made by the liver.[3]
Insulin lispro was first approved for use in the United States in 1996.[3][6][7] It is a manufactured analogue of human insulin where two amino acids have swapped positions.[8] In 2021, it was the 55th most commonly prescribed medication in the United States, with more than 12 million prescriptions.[9][10]
Humalog label
was invoked but never defined (see the help page).